NCT00523211View on ClinicalTrials.gov

Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5)

PHASE3CompletedINTERVENTIONAL
Enrollment

506

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

March 31, 2011

Conditions
HIV InfectionsAcquired Immunodeficiency Syndrome
Interventions
DRUG

Vicriviroc

One tablet of vicriviroc 30 mg once daily.

DRUG

Placebo

One tablet of placebo once daily.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00523211 - Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5) | Biotech Hunter | Biotech Hunter